MedTrace Logo

First In Human Study of CX-2051 in Advanced Solid Tumors

NCT06265688 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2026-05-19

No results posted yet for this study

Summary

The purpose of this first-in-human study, CTMX-2051-101, is to characterize the safety, tolerability, and antitumor activity of CX-2051 as a monotherapy and in combination with bevacizumab in adult participants with advanced solid tumors.

Conditions

  • Solid Tumor, Adult

Interventions

DRUG

CX-2051

Investigational drug

DRUG

Bevacizumab

IV infusion

Sponsors & Collaborators

  • CytomX Therapeutics

    lead INDUSTRY

Principal Investigators

  • Monika Vainorius, MD · CytomX Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-02
Primary Completion
2027-11-30
Completion
2029-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06265688 on ClinicalTrials.gov